5 Critical Things Not to Overlook in Today's Trading: Market Recon

With all the attention-grabbing headlines out there, don't forget about the Treasury auction, CPI data and these other critical issues.

Pfizer's China Exposure Could Dampen Its Reshuffle Hopes

For Pfizer, China is third largest market and a growing area of concern.

Pfizer Is Not at a Buy Point, but Here's an Options Play on the Name

Try this buy-write strategy to get a piece of PFE on its headline-grabbing news.

Trade Wars Are Back in the Headlines but the Market Still Isn't Very Worried

This is likely to be quickly forgotten again and the focus turn to earnings.

Winners (and Losers) From the China Trade War: Market Recon

Cloud and defense are still looking good, but watch out for retail names.

A Market That Continues to Climb a Wall of Many Worries

Maybe the worries are well justified but this market just doesn't care right now.

Jim Cramer: Why Brett Kavanaugh Would Be Good for the Stock Market

He is focused on curtailing the power of regulators, agencies and government.

4 Big Reasons Why This Market Is Ignoring the Pessimists

Bad news just can't seem to kill an aging bull market.

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.